Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of retinal vein occlusion
4.1.1.2. Rising development of novel drugs
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.2.2. XX
4.1.3. Opportunities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Pipeline Analysis
5.5. Epidemiology
5.6. Patent Analysis
5.7. Regulatory Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Central Retinal Vein Occlusion (CRVO)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Branch Retinal Vein Occlusion (BRVO)
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Ranibizumab
7.2.4. Faricimab
7.2.5. Aflibercept
7.3. Corticosteroids
7.3.1. Dexamethasone
7.3.2. Triamcinolone Acetonide
7.4. Laser Therapy
7.5. Surgery
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Bayer AG*
10.1.1. Company Overview
10.1.2. Type Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Regeneron Pharmaceuticals Inc.
10.3. F. Hoffmann-La Roche Ltd
10.4. Teva Pharmaceutical Industries Ltd.
10.5. AbbVie.
10.6. Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd.
10.7. KODIAK SCIENCES INC.
10.8. TAIWAN LIPOSOME CO., LTD.
LIST NOT EXHAUSTIVE
11. Appendix
11.1. About Us and Services
11.2. Contact Us